Matt Gline, Roivant CEO (courtesy Roivant)

A deal? An as­set sale? A launch? Every­one is watch­ing next moves for Roivant, Bridge­Bio

What’s next for two of biotech’s once-cool, now-hot com­pa­nies?

Hot on the heels of crit­i­cal da­ta read­outs, Roivant Sci­ences and Bridge­Bio Phar­ma are en­joy­ing two …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.